Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The findings, ...
TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...
Supplementary biologics license application planned for submission to the U.S. Food and Drug Administration in the first quarter of 2025 “All currently FDA-approved anti-VEGF therapies for retinal ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果